New‐Onset Headache After SARS ‐ CoV ‐2 Infection and Vaccination: Results From Three Population‐Based Cohorts in Norway
European Journal of Neurology · 2025
DOI: 10.1111/ene.70437 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Kristine Blix und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. Hauptthemen laut MEDLINE: COVID-19, Headache, COVID-19 Vaccines, Vaccination. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Norwegian Institute of Public Health, Norges Forskningsråd.
Abstract (Originalsprache)
Background
Persistent headache after SARS‐CoV‐2 infections and vaccination has been reported. However, limited data exist on the risk of new‐onset headache after these exposures compared to unexposed periods in the general population.
Methods
We used data from three population‐based cohorts ( N = 85,774, age 19–81 years). SARS‐CoV‐2 infections and vaccinations were obtained from national registries and questionnaires. Before and after Omicron emergence, participants stated whether they had been suffering from headache during the past year, reported headache characteristics, and time of onset. Time‐dependent exposures were used to investigate the impact of SARS‐CoV‐2 infection and vaccination on the risk of new‐onset headache. Headache subtypes were secondary outcomes.
Results
SARS‐CoV‐2 infection and first and second vaccine doses were associated with increased risk of new‐onset headache. The three cohorts, representing different age groups, were analyzed separately. For pre‐Omicron infections, the hazard ratio (HR) was 6.7 (95% confidence interval (CI) 4.8–9.2) and 6.5 (95% CI 3.8–11.1) among middle‐aged women and men, respectively. For Omicron infection, HRs were 4.7 (95% CI 4.1–5.4) and 4.5 (95% CI 3.7–5.4), respectively. The risk increased with infection severity. Corresponding HRs for first and second vaccine doses, administered during low transmission, were 1.6 and 1.7, respectively, in women, and 1.5 for both doses in men. The third dose, given before the Omicron surge, was associated with 20%–40% protection against new‐onset headache.
Conclusions
SARS‐CoV‐2 infection was strongly associated with new‐onset headache. Primary vaccination was associated with a small increased risk of headache during a low‐transmission period, whereas booster vaccination offered protection during high‐transmission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway.
- Center for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
- NorHead, Norwegian Headache Research Centre, Norwegian University of Science and Technology, Trondheim, Norway.
ORCID-Profile: Ida Henriette Caspersen, Siri N Skodvin, Marte-Helene Bjørk
Förderung
- Norwegian Institute of Public Health
- Norges Forskningsråd
Zitieren
APA
Blix, K., Laake, I., Caspersen, I. H., Feiring, B., Robertson, A. H., Skodvin, S. N., Mjaaland, S., Magnus, P., Stubberud, A., Bjørk, M. H., & Trogstad, L. (2025). New‐Onset Headache After SARS ‐ CoV ‐2 Infection and Vaccination: Results From Three Population‐Based Cohorts in Norway. European Journal of Neurology. https://doi.org/10.1111/ene.70437
Vancouver
Blix K, Laake I, Caspersen IH, Feiring B, Robertson AH, Skodvin SN, et al. New‐Onset Headache After SARS ‐ CoV ‐2 Infection and Vaccination: Results From Three Population‐Based Cohorts in Norway. European Journal of Neurology. 2025. doi:10.1111/ene.70437
BibTeX
@article{Blix2025,
author = {Blix, Kristine and Laake, Ida and Caspersen, Ida Henriette and Feiring, Berit and Robertson, Anna Hayman and Skodvin, Siri N and Mjaaland, Siri and Magnus, Per and Stubberud, Anker and Bjørk, Marte-Helene and Trogstad, Lill},
title = {New‐Onset Headache After SARS ‐ CoV ‐2 Infection and Vaccination: Results From Three Population‐Based Cohorts in Norway},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70437}
}
EUVIMED